Efficacy and Safety of Venetoclax in Combination with Gilteritinib for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia in the Expansion Cohort of a Phase 1b Study

被引：23
|
作者：
Daver, Naval
Altman, Jessica K.
Maly, Joseph
Levis, Mark
Ritchie, Ellen
Litzow, Mark
McCloskey, James K.
Smith, Catherine C.
Schiller, Gary J.
Bradley, Terrence
Tiu, Ramon V.
Hong, Wan-Jen
Tong, Bo
Qin, Qin
Dilley, Kimberley
Perl, Alexander E.
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-139705
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [11] Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed/refractory acute myeloid leukemia
    Naoko Hosono
    Hisayuki Yokoyama
    Nobuyuki Aotsuka
    Kiyoshi Ando
    Hiroatsu Iida
    Takayuki Ishikawa
    Kensuke Usuki
    Masahiro Onozawa
    Masahiro Kizaki
    Kohmei Kubo
    Junya Kuroda
    Yukio Kobayashi
    Takayuki Shimizu
    Shigeru Chiba
    Miho Nara
    Tomoko Hata
    Michihiro Hidaka
    Shin-Ichiro Fujiwara
    Yoshinobu Maeda
    Yasuyoshi Morita
    Mikiko Kusano
    Qiaoyang Lu
    Shuichi Miyawaki
    Erhan Berrak
    Nahla Hasabou
    Tomoki Naoe
    International Journal of Clinical Oncology, 2021, 26 : 2131 - 2141
  • [12] Gilteritinib in combination with venetoclax, low-dose cytarabine and actinomycin D for relapsed or refractory FLT3-mutated acute myeloid leukaemia
    Zucenka, Andrius
    Griskevicius, Laimonas
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (04) : 1227 - 1231
  • [13] A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
    Short, Nicholas J.
    Ravandi, Farhad
    Daver, Naval
    Dinardo, Courtney D.
    Borthakur, Gautam
    Kadia, Tapan M.
    Yilmaz, Musa
    Issa, Ghayas C.
    Abramova, Regina
    Garza, Araceli Isabella
    Kantarjian, Hagop M.
    Abbas, Hussein A.
    BLOOD, 2024, 144
  • [14] Gilteritinib-based combination therapy in adult relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Chen, Nianci
    Pan, Jiajia
    Zhou, Yile
    Mao, Liping
    Lou, Yinjun
    Qian, Jiejing
    Xu, Gaixiang
    Wei, Juying
    Zhou, De
    Shou, Lihong
    Huang, Li
    Yan, Minchao
    Zeng, Hui
    Fan, Cuihua
    Wu, Gongqiang
    Feng, Weiying
    Tong, Hongyan
    Jin, Jie
    Wang, Huafeng
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (03) : 861 - 870
  • [15] Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia
    Chen, Nianci
    Zhou, Yile
    Tong, Hongyan
    Wei, Juying
    Lou, YinJun
    Zhou, De
    Fan, Cuihua
    Huang, Li
    Mao, Liping
    Li, Chenying
    Wang, Huafeng
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [16] Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia
    Wang, Jianxiang
    Jiang, Bin
    Li, Jian
    Liu, Ligen
    Du, Xin
    Jiang, Hao
    Hu, Jianda
    Yuan, Menghe
    Sakatani, Taishi
    Kadokura, Takeshi
    Takeuchi, Masato
    Kosako, Masanori
    Ma, Xiao
    Girshova, Larisa
    Tan, Jerome
    Bondarenko, Sergey
    Lee, Lily Wong Lee
    Khuhapinant, Archrob
    Martynova, Elena
    Hasabou, Nahla
    LEUKEMIA, 2024, 38 (11) : 2410 - 2418
  • [17] Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
    Short, Nicholas J.
    Daver, Naval
    Dinardo, Courtney D.
    Kadia, Tapan
    Nasr, Lewis F.
    Macaron, Walid
    Yilmaz, Musa
    Borthakur, Gautam
    Montalban-Bravo, Guillermo
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Chien, Kelly S.
    Jabbour, Elias
    Nasnas, Cedric
    Huang, Xuelin
    Qiao, Wei
    Matthews, Jairo
    Stojanik, Christopher J.
    Patel, Keyur P.
    Abramova, Regina
    Thankachan, Jennifer
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (13) : 1499 - 1508
  • [18] Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3Mutated Acute Myeloid Leukemia
    Daver, Naval
    Perl, Alexander E.
    Maly, Joseph
    Levis, Mark
    Ritchie, Ellen
    Litzow, Mark R.
    McCloskey, James
    Smith, Catherine C.
    Schiller, Gary J.
    Bradley, Terrence
    Tiu, Ramon V.
    Naqvi, Kiran
    Dail, Monique
    Siddani, Satya
    Wang, Jing
    Chyla, Brenda
    Lee, Paul
    Altman, Jessica K.
    BLOOD, 2021, 138
  • [19] A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study
    Short, Nicholas J.
    DiNardo, Courtney D.
    Daver, Naval
    Nguyen, Daniel
    Yilmaz, Musa
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Huang, Xuelin
    Qiao, Wei
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Chien, Kelly S.
    Borthakur, Gautam
    Delumpa, Ricardo
    Milton, Anna
    Pierce, Sherry A.
    Jabbour, Elias J.
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    BLOOD, 2021, 138
  • [20] Gilteritinib or venetoclax in relapsed or refractory FLT3mut acute myeloid leukemia
    Murray, Graeme
    Bouligny, Ian Michael
    Patel, Tilak
    Doyel, Michael
    Boron, Josh
    Tran, Valerie
    Gor, Juhi
    Hang, Yiwei
    Ho, Thuy
    Zacholski, Kyle
    Venn, Chad Michael
    Alnimer, Yanal Mufeed
    Wages, Nolan
    Grant, Steven
    Maher, Keri Renee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345